

JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T -210J, Shahpur Jat, New Delhi -110049 (India)


FAX: 0091- 11- 26498341, 26494708 Phone: 0091-11-26494519-24

CIN No:- L74899DL1978PLC009181

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

(Rs. in lakhs)

Sl. No.	Particulars	Quarter ended			12 Months Year ended
		30.06.2022	30.06.2021	31.03.2022	31.03.2022
		Unaudited	Unaudited	Audited	Audited
1	Revenue from operations				
	a) Net sales / income from operations	6,059.69	5,405.48	5,122.66	21,758.42
	b) Other operating Income				
	Total revenue from operations	6,059.69	5,405.48	5,122.66	21,758.42
2	Other Income	31.35	82.18	27.57	333.60
3	Total income [1+2]	6,091.04	5,487.66	5,150.23	22,092.02
4	Expenses				
	a) Cost of materials consumed	1,117.92	845.12	87.47	3,190.64
	b) Purchases of stock-in-trade	1,246.71	1,141.41	1,237.30	4,975.44
	c) Changes in inventories of finished goods, work-in-progress and stock in trade	187.96	76.09	981.58	561.12
	d) Employee benefits expense	1,488.15	1,438.66	1,407.47	5,767.52
	e) Finance costs	1.38	10.54	5.82	28.51
	f) Depreciation and amortisation expense	19.32	28.34	64.50	152.62
	g) Other expenses	1,377.14	976.74	1,346.07	4,684.27
	Total expenses	5,438.58	4,516.91	5,130.21	19,360.12
5	Profit before exceptional items and taxes (3-4)	652.46	970.75	20.02	2,731.91
6	Exceptional Items	580.43			
7	Total Profit before taxes (5-6)	72.03	970.75	20.02	2,731.91
8	Tax expense:				
	a) Current Tax	81.86	284.60	(10.95)	740.33
	b) Deferred Tax	(46.76)	1.34	28.47	32.88
	Profit after tax [7-8]	36.93	684.81	2.50	1,958.70
9	Other comprehensive income				
10	a) (i) Items that will not be classified to profit or loss	-	-	191.62	191.62
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	-	(55.80)	(55.80)
	Total other comprehensive income [A(i) + A(ii)]	-	-	135.82	135.82
	Total comprehensive Income [9+10]	36.93	684.81	138.32	2,094.52
11	Paid up equity share capital (face value Rs. 5/- each)	1,309.90	1,309.90	1,309.90	1,309.90
12	Other equity				
	a) Basic (Rs.)	0.14	2.61	0.01	7.48
	b) Diluted (Rs.)	0.14	2.61	0.01	7.48



Note for Results:

- 1 The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 09, 2022. The results have been subjected to Unaudited review by Statutory Auditors of the Company.
- 2 In line with the provisions of Ind AS 18, the Company operates in one reportable business segment i.e., 'Pharmaceuticals'.
- 3 Figures for the previous periods have been regrouped, wherever necessary, to correspond with the figures of the current period.
- 4 The above results are available on website of the company www.jagsonpal.com and on the Website of BSE (www.bseindia.com) and NSE (www.nseindia.com).
- 5 The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
- 6 The revenues for the reported periods are net of GST.
- 7 Provision for taxation includes provision for current tax.
- 8 Fixed Assets relating to Faridabad factory and Delhi Head Office have been impaired to the tune of INR 278 Lakhs during Quarter.
- 9 Intangible Assets have been written off to the tune of INR 235 Lakhs during Quarter.
- 10 One-time Ex-Gratia amount of INR 68 Lakhs have been paid to the retiring employees during the Quarter.

Place : New Delhi
Date : 09 August 2022



By Order of the Board
For Jagsonpal Pharmaceuticals Limited




Manish Gupta
Managing Director
DIN No 06805265